Mara Zielinski

Mara Zielinski

Auto-generated profile, based on publicly available information

Mara Zielinski

Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich, Jülich, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMarie P. Schützmann
Marie P. Schützmann
FHFilip Hasecke
Filip Hasecke
SBSarah Buchholz
Sarah Buchholz
MZMara Zielinski
Mara Zielinski
SHSebastian Hänsch
Sebastian Hänsch
WHWolfgang Hoyer
Wolfgang Hoyer
Amyloid-β peptide (Aβ) forms metastable oligomers >50 kDa, termed AβOs, that are more effective than Aβ amyloid fibrils at triggering Alzheimer’s disease-related processes such as synaptic dysfunction and Tau pathology, including Tau mislocalization. In neurons, Aβ accumulates in endo-lysosomal vesicles at low pH. Here, we show that the rate of AβO assembly is accelerated 8,000-fold upon pH reduction from extracellular to endo-lysosomal pH, at the expense of amyloid fibril formation. The pH-induced promotion of AβO formation and the high endo-lysosomal Aβ concentration together enable extensive AβO formation of Aβ42 under physiological conditions. Exploiting the enhanced AβO formation of the dimeric Aβ variant dimAβ we furthermore demonstrate targeting of AβOs to dendritic spines, potent induction of Tau missorting, a key factor in tauopathies, and impaired neuronal activity. The results suggest that the endosomal/lysosomal system is a major site for the assembly of pathomechanistically relevant AβOs.

16 November 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
MZMara Zielinski
Mara Zielinski
FRFernanda S. Peralta Reyes
Fernanda S. Peralta Reyes
LGLothar Gremer
Lothar Gremer
SSSarah Schemmert
Sarah Schemmert
BFBenedikt Frieg
Benedikt Frieg
GSGunnar F. Schröder
Gunnar F. Schröder
The use of transgenic mice displaying amyloid-β (Aβ) brain pathology has been essential for the preclinical assessment of new treatment strategies for Alzheimer’s disease. However, the properties of Aβ in such mice have not been systematically compared to Aβ in the brains of patients with Alzheimer’s disease. Here, we determined the structures of nine ex vivo Aβ fibrils from six different mouse models by cryogenic-electron microscopy. We found novel Aβ fibril structures in the APP/PS1, ARTE10 and tg-SwDI models, whereas the human type II filament fold was found in the ARTE10, tg-APPSwe and APP23 models. The tg-APPArcSwe mice showed an Aβ fibril whose structure resembles the human type I filament found in patients with sporadic Alzheimer’s disease. A detailed assessment of the Aβ fibril structure is key to the selection of adequate mouse models for the preclinical development of novel plaque-targeting therapeutics and positron emission tomography imaging tracers in Alzheimer’s disease.

11 August 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
MVMaría Pagnon de la Vega
María Pagnon de la Vega
VGVilmantas Giedraitis
Vilmantas Giedraitis
WMWojciech Michno
Wojciech Michno
LKLena Kilander
Lena Kilander
GGGökhan Güner
Gökhan Güner
MIMartin Ingelsson
Martin Ingelsson
The Uppsala APP deletion leads to Alzheimer’s disease by modulating α- and β-secretase cleavage of APP and by accelerating Aβ fibrillization.

1 August 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MZMara Zielinski
Mara Zielinski
CRChristine Röder
Christine Röder
GSGunnar F. Schröder
Gunnar F. Schröder
Amyloids share a common architecture but play disparate biological roles in processes ranging from bacterial defense mechanisms to protein misfolding diseases. Their structures are highly polymorphic, which makes them difficult to study by X-ray diffraction or NMR spectroscopy. Our understanding of amyloid structures is due in large part to recent advances in the field of cryo-EM, which allows for determining the polymorphs separately. In this review, we highlight the main stepping stones leading to the substantial number of high-resolution amyloid fibril structures known today as well as recent developments regarding automation and software in cryo-EM. We discuss that sample preparation should move closer to physiological conditions to understand how amyloid aggregation and disease are linked. We further highlight new approaches to address heterogeneity and polymorphism of amyloid fibrils in EM image processing and give an outlook to the upcoming challenges in researching the structural biology of amyloids.

17 December 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
ACAbhishek Cukkemane
Abhishek Cukkemane
NBNina Becker
Nina Becker
MZMara Zielinski
Mara Zielinski
BFBenedikt Frieg
Benedikt Frieg
NLNils-Alexander Lakomek
Nils-Alexander Lakomek
OWOliver H. Weiergräber
Oliver H. Weiergräber
Chronic mental illnesses (CMIs) pose a significant challenge to global health due to their complex and poorly understood etiologies and hence, absence of causal therapies. Research of the past two decades has revealed dysfunction of the disrupted in schizophrenia 1 (DISC1) protein as a predisposing factor involved in several psychiatric disorders. DISC1 is a multifaceted protein that serves myriads of functions in mammalian cells, for instance, influencing neuronal development and synapse maintenance. It serves as a scaffold hub forming complexes with a variety (~300) of partners that constitute its interactome. Herein, using combinations of structural and biophysical tools, we demonstrate that the C-region of the DISC1 protein is highly polymorphic, with important consequences for its physiological role. Results from solid-state NMR spectroscopy and electron microscopy indicate that the protein not only forms symmetric oligomers but also gives rise to fibrils closely resembling those found in certain established amyloid proteinopathies. Furthermore, its aggregation as studied by isothermal titration calorimetry (ITC) is an exergonic process, involving a negative enthalpy change that drives the formation of oligomeric (presumably tetrameric) species as well as β-fibrils. We have been able to narrow down the β-core region participating in fibrillization to residues 716–761 of full-length human DISC1. This region is absent in the DISC1Δ22aa splice variant, resulting in reduced association with proteins from the dynein motor complex, viz., NDE-like 1 (NDEL1) and lissencephaly 1 (LIS1), which are crucial during mitosis. By employing surface plasmon resonance, we show that the oligomeric DISC1 C-region has an increased affinity and shows cooperativity in binding to LIS1 and NDEL1, in contrast to the noncooperative binding mode exhibited by the monomeric version. Based on the derived structural models, we propose that the association between the binding partners involves two neighboring subunits of DISC1 C-region oligomers. Altogether, our findings highlight the significance of the DISC1 C-region as a crucial factor governing the balance between its physiological role as a multifunctional scaffold protein and aggregation-related aberrations with potential significance for disease.

31 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MZMara Zielinski
Mara Zielinski
FRFernanda S. Peralta Reyes
Fernanda S. Peralta Reyes
LGLothar Gremer
Lothar Gremer
SSSarah Schemmert
Sarah Schemmert
BFBenedikt Frieg
Benedikt Frieg
GSGunnar F. Schröder
Gunnar F. Schröder
The development of novel drugs for Alzheimer’s disease has proven difficult, with a high failure rate in clinical trials. Typically, transgenic mice displaying amyloid-β peptide brain pathology are used to develop therapeutic options and to test their efficacy in preclinical studies. However, the properties of Aβ in such mice have not been systematically compared to Aβ from the patient brains. Here, we determined the structures of nine ex vivo Aβ fibrils from six different mouse models by cryo-EM. We found novel Aβ fibril structures in the APP/PS1, ARTE10, and tg-SwDI models, whereas the human familial type II fibril fold was found in the ARTE10, tg-APP Swe , and APP23 models. The tg-APP ArcSwe mice showed an Aβ fibril whose structure resembles the human sporadic type I fibril. These structural elucidations are key to the selection of adequate mouse models for the development of novel plaque-targeting therapeutics and PET imaging tracers. One Sentence Summary: Cryo-EM structures of Aβ fibrils extracted from brains of mouse models used for Alzheimer’s disease preclinical research are presented.